HCW Biologics (NASDAQ:HCWB) Director Scott Garrett Acquires 7,736 Shares of Stock

HCW Biologics Inc. (NASDAQ:HCWB) Director Scott Garrett purchased 7,736 shares of the firm’s stock in a transaction on Wednesday, July 29th. The shares were acquired at an average price of $2.58 per share, with a total value of $19,958.88. Following the purchase, the director directly owned 41,644 shares in the company, valued at $107,441.52. This represents a 22.81% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

HCW Biologics Trading Up 1.6%

NASDAQ HCWB traded up $0.05 during trading hours on Friday, hitting $3.20. The company’s stock had a trading volume of 61,185 shares, compared to its average volume of 1,508,655. The company has a market capitalization of $5.11 million, a PE ratio of -0.06 and a beta of 2.29. HCW Biologics Inc. has a 52 week low of $1.50 and a 52 week high of $44.10. The company’s 50-day simple moving average is $6.78 and its two-hundred day simple moving average is $5.21.

HCW Biologics (NASDAQ:HCWB) last announced its earnings results on Thursday, May 14th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.64) by $3.01. HCW Biologics had a negative return on equity of 486.87% and a negative net margin of 34.73%.The company had revenue of $6.54 million for the quarter, compared to analysts’ expectations of $6.54 million.

Institutional Trading of HCW Biologics

An institutional investor recently bought a new stake in HCW Biologics stock. Armistice Capital LLC purchased a new stake in shares of HCW Biologics Inc. (NASDAQ:HCWB) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned 9.15% of HCW Biologics as of its most recent SEC filing. 2.96% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on HCWB shares. Maxim Group boosted their price target on shares of HCW Biologics from $12.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Wall Street Zen raised shares of HCW Biologics to a “hold” rating in a research report on Saturday, May 23rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of HCW Biologics in a research note on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, HCW Biologics currently has a consensus rating of “Hold” and a consensus target price of $30.00.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.